Option chain shows key data for Willamette Valley's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Willamette Valley.

Willamette Valley (NASDAQ:WVVI) Stock, Option Chain

Willamette Valley

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

penny stocks tips 1

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ABIO

CYAN

DOUG

WVVI

Citizens And 4 Other Stocks Under $5 Insiders Are Buying

Pioneering Pinot Noir In The Pacific Northwest - Meet One Of The Founders Of A Now World-Class Wine Region

Movers & Shakers

Interview

General

Sign up for this week’s All Access giveaway here! 

grapes

Topics

Small Cap

BF-B

BF.B

NAPA

NWINF

PERNOD RICARD S A SP/ADR by Pernod Ricard S.A.

PRNDY

Numbers vary wildly as to the total number of local independent wineries globally and in North America, with tabulations going as high as 65,000 worldwide and 14,000 in the U.S.

A Club Where Buying Wine Is Not Just An Avocation But An Investment In The Winemakers Themselves

Willamette Valley Vineyards, Inc. - Common Stock

Willamette Valley Vineyards Inc

Willamette Valley Vineyards, Inc. - Series A Redeemable Preferred Stock

Earnings

Willamette Valley Vineyards Diluted $(0.17) Inline YoY; Revenue $9.370M Up From $9.348M YoY

Willamette Valley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) reported quarterly losses of $(0.07) per share. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported $10.33 million in sales this quarter. This is a 3.69 percent decrease over sales of $10.73 million the same period last year.

Willamette Valley Q2 EPS $(0.07) Up From $(0.08) YoY, Sales $10.33M Down From $10.73M YoY

The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 408,777 shares at</a> an average price of $3.49. To acquire these shares, it cost around $1.4 million.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) President and CEO Jon Stenberg <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 4,580 shares at</a> an average price of $2.59. To acquire these shares, it cost around $11,862.</li>
<li>What's Happening: On July 1, Citizens President Jon Stenberg was appointed Chief Executive Officer.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3 class="wp-block-heading">Willamette Valley Vineyards</h3>
<ul>
<li>The Trade: Willamette Valley Vineyards, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) CEO James W Bernau <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,978 shares</a> at an average price of $3.92. The insider spent around $11,682 to buy those shares. </li>
<li>What's Happening: On May 13, the company said sales revenue for the three months ended March 31, 2024 and 2023 was $8,803,080 and $8,308,940, respectively.</li>
<li>What Willamette Valley Vineyards Does: Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis a<a href="https://www.benzinga.com/quote/aei/analyst-ratings">cquired a total of 10,000 shares</a> at an average price of $0.42. The insider spent around $4,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Douglas Elliman</h3>
<ul>
<li>The Trade: Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) Director Mark Zeitchick <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 40,000 shares</a> at an average price of $1.18. The insider spent $47,196 to buy those shares.</li>
<li>What's Happening: On July 2, Douglas Elliman announced that it secured a $50 million growth investment from Kennedy Lewis Investment Management.</li>
<li>What Douglas Elliman Does: Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39748049/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings</a></li>
</ul>

Willamette Valley Vineyards Reports 2023 Net Sales Of $39.13M, Up 15.3% Y/Y; Loss Per Share $(0.65) Vs Loss $(0.51) Last year

Willamette Valley Vineyards Q3 2023 EPS $(0.17) Up From $(0.29) YoY, Revenue $9.348M Up From $7.602M YoY,

Willamette Valley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) reported quarterly losses of $(0.08) per share. This is a 100 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $10.73 million in sales this quarter. This is a 23.28 percent increase over sales of $8.70 million the same period last year.

Willamette Valley Q2 EPS $(0.08) Down From $(0.04) YoY, Sales $10.73M Up From $8.70M YoY

Willamette Valley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) reported quarterly losses of $(0.07) per share. This is a 187.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported $11.39 million in sales this quarter. This is a 20.76 percent increase over sales of $9.43 million the same period last year.

Willamette Valley Q4 Adj. EPS $(0.07) Down From $0.08 YoY, Sales $11.39M Up From $9.43M YoY

Willamette Valley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) reported quarterly losses of $(0.29) per share. This is a 1550 percent decrease over earnings of $0.02 per share from the same period last year. The company reported $7.60 million in sales this quarter. This is a 0.50 percent decrease over sales of $7.64 million the same period last year.

Willamette Valley Q3 EPS $(0.29) Down From $0.02 YoY, Sales $7.60M Down From $7.64M YoY

Sign up for this week&rsquo;s All Access giveaway <a href="https://www.benzinga.com/events/all-access-stocks/#analysis">here</a>!&nbsp;
Jim Bernau, Founder and CEO of Willamette Valley Vineyards (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>), was a guest on Benzinga&rsquo;s All Access on October 14, 2022.
Willamette Valley Vineyards is one of the largest wine producers in Oregon. The company, founded in 1973, was an early visionary in the region, helping to raise the profile of Oregon wines around the globe. The region and its wines, especially Pinot Noirs, are now considered to be amongst the very best in the world.
Watch the full interview here:
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/X_Yw6chi41M?start=5706" width="560"></iframe>
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

&nbsp;Willamette Valley Vineyards (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>, WVVIP)))) or (&quot;Willamette&quot;),&nbsp;Oregon&#39;s&nbsp;certified sustainable, leading winery and producer of Pinot Noir, is teaming with TiiCKER, the world&#39;s premier direct-to-shareholder loyalty and rewards platform, to maximize its 2022 Preferred Stock Offering to fund growth.
<a href="https://mma.prnewswire.com/media/1920799/Willamette_Valley_Vineyards.html" target="_blank"><img alt="Willamette Valley Vineyards Logo" src="https://mma.prnewswire.com/media/1920799/Willamette_Valley_Vineyards.jpg" /></a>
Willamette Valley Vineyards has partnered with TiiCKER for several years to maximize its Preferred Stock Offering to fund growth while rewarding retail shareholders with unique rewards and perks (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3676484-1&amp;h=718615077&amp;u=https%3A%2F%2Fwww.tiicker.com%2Fbrand%2FWVVIP&amp;a=www.TiiCKER.com%2FWVVIP" target="_blank">www.TiiCKER.com/WVVIP</a>). Individual investors in Willamette Valley Vineyards preferred stock enjoy discounts, owner-only experiences, exclusive access to new releases and the opportunity to take dividends in wine credit.
Willamette Valley Vineyards pioneered the community-funded business model in 1989. The Preferred Stock Offering (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3676484-1&amp;h=2400438580&amp;u=https%3A%2F%2Fwww.wvv.com%2FOwnership&amp;a=www.wvv.com%2FOwnership" target="_blank">www.wvv.com/Ownership</a>) is intended to fund the expansion of the&nbsp;Oregon&nbsp;winery and its growing portfolio of tasting rooms, restaurants and production facilities, such as the company&#39;s new sparkling winery Domaine Willamette in&nbsp;Oregon&#39;s&nbsp;Dundee Hills. Investors may purchase shares at&nbsp;$5.25&nbsp;per share, offering an annual&nbsp;4.19%&nbsp;dividend or wine credit with&nbsp;15%&nbsp;more value, if your application and subscription agreement are received or postmarked by&nbsp;October 31, 2022, and accepted.&nbsp;The minimum purchase is 300 shares&nbsp;($1,575)&nbsp;and the maximum purchase is 2,300 shares&nbsp;($12,075.00). The share price will increase to&nbsp;$5.35&nbsp;on&nbsp;November 1, 2022.&nbsp;Priority to become Owners is given to wine enthusiasts who will support their investment as Wine Club Members or use their dividends as wine credits.
&quot;As wine enthusiasts own the winery, they are providing the capital to obtain top talent, vineyards and equipment. They are also fueling our growth with the purchasing and wine recommendations they make to their friends and neighbors,&quot; said Willamette Valley Vineyards Founder and CEO&nbsp;Jim Bernau. &quot;Partnering with TiiCKER aligns perfectly with our mission and allows us to expand our reach to wine enthusiasts and foodies looking for an investment that fits their lifestyle and gives them the perks of ownership.&quot;
TiiCKER Founder and CEO,&nbsp;Jeff Lambert, added, &quot;Willamette Valley Vineyards believes in connecting with shareholders and TiiCKER&#39;s platform is perfectly suited to not only verify ownership to validate WVVI shareholder perks, but to also connect with other investors who love great wine.&quot;
WVVI was the first SEC-authorized, community-funded business in the nation, spurring a growing number of laws allowing for community-based funding of other small businesses across the country. Founder&nbsp;Jim Bernau&#39;s&nbsp;vision of creating world-class wine via shared ownership inspired wine enthusiasts investing in common (WVVI) and preferred (WVVIP) stock, producing tens of thousands of enthusiastic Owners to date.
TiiCKER rewards shareholders in Willamette Valley Vineyards by granting unprecedented access to next-level perks, commission-free trading and customized content unique to their investment and lifestyle interests. TiiCKER verifies ownership on behalf of company brand partners &ndash; like WVVI &ndash; and offers new ways to connect, engage and reward their owners.

Willamette Valley Vineyards Offers Preferred Stock Ownership Through TiiCKER For Limited Time

Numbers vary wildly as to the total number of local independent wineries globally and in North America, with tabulations going as high as 65,000 worldwide and 14,000 in the U.S. &mdash; but a recent study from Wines &amp; Vines magazine was a bit more conservative, revealing 8,391 wineries in North America; 7,762 in the United States; 568 in Canada (primarily British Columbia and Ontario); and 61 in Mexico. One thing not up for debate? There&rsquo;s a lot of wine available in North America and the world.
Some investors have also found the sheer amount of large wine producers to be a good bet, with publicly traded wine companies such as Constellation Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stz#NYSE">STZ</a>), Diageo PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deo#NYSE">DEO</a>), Brown-Forman Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bf-b#NYSE">BF-B</a>), Willamette Valley Vineyards Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>), Duckhorn Vineyards (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/napa#NYSE">NAPA</a>) and Pernod Ricard ADR (OTCMKTS: PRNDY).
But the trend of buying wine from local wineries has been a conscious consumer effort in recent years, partly because many of those smaller wineries are passionate about producing a great sustainable product.
To help support their efforts, a glut of wine clubs have hit the market, all with the promise of providing selections supporting local independent growers from California and Oregon to France, Italy, Argentina and Australia. With the pandemic moving consumers to order wine from around the world online, a number of new wine subscription services appeared in 2020.
But in any crowded consumer market, building differentiation can become the catalyst for growth. One standout, international wine club, 12-year-old United Kingdom-based Naked Wines PLC (OTCMKTS: NWINF), with U.S. headquarters in Napa Valley, California, believes it has found a unique twist to grab a market that wants to not only feel they&rsquo;re helping local winemakers through the purchase of their products but by becoming an investor.
Naked Wines reports that it works with over 166 independent and unique winemakers worldwide, selling its high-end bottled wine for relatively low prices but with a twist. The company calls its 300,000 subscription members &ldquo;Angels&rdquo; (as in Angel investors), with the goal of funding independent winemakers upfront so they can concentrate solely on making good wine, forgoing the expensive costs associated with the traditional retail model of loans. The customer in return gets world-class, high-quality wines for an average of 60% less than the cost of traditional retail pricing.&nbsp;
Insider.com called the Naked Wine selection process a &ldquo;Shark Tank for their industry,&rdquo; &nbsp;where independent winemakers propose a wine to win approval. The company&rsquo;s customers, called &ldquo;Angels&rdquo;, &nbsp;then act as funding investors, depositing a $40 monthly contribution into their
Naked Wines account that they then use at their discretion to order wine from the independent winemakers. Naked Wine promotes that the more Angels they have, the more winemakers they can fund to provide hand-crafted wines at wholesale prices up to 60% less than the market offers.
Naked Wines claims it not only cuts costs by eliminating sales and marketing expenses for the independent wineries but its upfront Angel-funding gives winemakers more time in the vineyard and less in the office. The company&#39;s members can also interact with the winemakers directly through its nakedwines.com mobile app.
The company is additionally currently <a href="https://www.nakedwines.com/BENZINGA100">offering promotions such as</a> $100 off of 6pk of Wine for $39.99 with shipping included.
For more information about Naked Wines, visit <a href="http://www.nakedwines.com">www.nakedwines.com</a>.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
&nbsp; 
Featured photo by JillWellington on <a href="https://pixabay.com/photos/grapes-wine-grapes-purple-grapes-1952035/">Pixabay</a>

The U.S. wine industry, which dates to the 1560s, rapidly expanded from a series of scattered, small-scale vineyards to widespread production over several centuries.&nbsp;
Though it&rsquo;s now centuries old, the industry is still growing with an estimated compound annual growth rate of <a href="https://www.grandviewresearch.com/industry-analysis/us-wine-market#:~:text=How%20big%20is%20the%20U.S.,USD%2066.97%20billion%20in%202022.">6.8%</a> and could exceed $115 billion by 2030.
However, a new generation of wine consumers is transforming the industry from one tied to tradition and luxury into a more casual and fun hobby that&rsquo;s accessible to wine drinkers of all experience levels. Here&rsquo;s a quick look at the history of winemaking in the United States and how new consumer trends are changing the shape of the industry.
<h2>A Brief History Of Winemaking In United States</h2>
When Europeans arrived in the United States in the 16th century, they immediately began making wine using a local grape called muscadine. Growing along most of the eastern seaboard and as far west as Texas, muscadine lent itself well to sweeter wines with a medium body and intense fruity flavors.
While every state still produces wine, the industry has become heavily concentrated in California where approximately <a href="https://wineinstitute.org/our-industry/statistics/california-us-wine-production/">81%</a> of U.S. wine is produced. The state&rsquo;s Mediterranean climate made it the perfect site for importing Spanish and Italian grape varietals that needed dry, sunny conditions to thrive.
That helped the country become one of the leading wine producers in the world, surpassed only by Italy, France and Spain. It&rsquo;s also helped the American wine industry grow into a $63 billion market by 2021.
Market leaders like Constellation Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stz#NYSE">STZ</a>) have traditionally dominated the market through sheer variety, producing and marketing a wide range of beverages, including wine, beer and spirits.&nbsp;
Meanwhile, others in the industry make a name for themselves by niching down into specific regions or varietals. Willamette Valley Vineyards Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>), for example, exclusively produces a variety of red and white wines in Oregon&rsquo;s Willamette Valley.
Others, like Duckhorn Portfolio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/napa#NYSE">NAPA</a>), compete by building up a portfolio of small, local wineries to offer a broader product line without sacrificing the premium, handcrafted quality of wines from smaller wineries.
But as consumer trends change and the market evolves, winemakers are finding new ways to make a name for themselves in a market where tradition has reigned supreme for centuries.
<h2>Younger Consumers Are Driving Innovation In An Old Industry</h2>
While reputation and tradition are still key to winning over older wine consumers, younger consumers want fun, innovation and a more casual wine-drinking experience while still being able to learn about different varietals, regions and what makes a premium wine.&nbsp;
As millennials and Gen Z account for a rapidly growing segment of wine drinkers, producers are answering those demands with more unique branding, alternative packaging and improved shopping experiences.
One of the most successful of these adaptations has been <a href="https://www.theiwsr.com/changing-millennial-preferences-drive-packaging-innovation-and-on-site-experiences-at-us-wineries/">on-the-go packaging</a>. Boxed wine, bagged wine, canned wine and other alternatives to the traditional glass bottle have helped the industry meet the needs of younger consumers who want to enjoy wine as part of a larger experience like hiking, boating or spending the day at the beach with friends.&nbsp;
<a href="https://splashbeveragegroup.com/">Splash Beverage Group Inc.&rsquo;s</a> (NYSEAMERICAN: SBEV) <a href="https://copadivino.com/">Copa di Vino</a>, for example, packages premium wine in a portable hourglass-shaped cup that&rsquo;s easy to carry and comes with a splash-proof cap so it can be closed and saved for later. There&rsquo;s no bulky glass, no need for a corkscrew, and the wine is already portioned out into glasses.
These often smaller formats also make it possible for millennials, who typically <a href="https://www.gallotrends.com/survey.php">drink less than older consumers</a>, to enjoy wine on these adventures without committing to an entire bottle. It&rsquo;s also better suited to adventurous wine drinkers who can more readily sample diverse wines by buying smaller, more affordable formats.&nbsp;&nbsp;
Image provided by <a href="https://www.shutterstock.com/image-photo/two-hands-three-full-plastic-cups-1360468667">shutterstock</a>
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Entertainment

Restaurants

U.S. Wine Industry Finds Innovative Ways To Adapt To More Adventurous, More Casual Millennial Wine Drinkers

Offerings

Willamette Valley Vineyards Inc Files For Mixed Shelf Of Up To $20M

Options

Intraday Update

Movers

QMCO

QTNT

RBOT

RCON

RCRT

RDHL

REAL

RELY

RiverNorth Flexible Municipal Income Fund, Inc. Common Stock

Lordstown Motors Corp. - Class A Common Stock

RIDE

RIOT

RIVN

RKLB

RLAY

RNXT

ROIV

ROOT

RPAY

Cohen & Steers Quality Income Realty Fund Inc

RRGB

RiverNorth Marketplace Lending Corporation Common Stock

RVPH 

RVSN

RXRX

SANG

SBTX

SBUX

SCOR

SDIG

SEAT

SENS

SFIX

SGRP

SHAK

SHCR

SHOP

SHYF

SIDU

SKIL

SKIN

SKLZ

SKYT

SLDB

SLGC

SLGG

SMED

SMFG

SMFL

SMMT

SNGX

SOLO

SOPA

SRAD

SRAX

SRNE

SSSS

STEM

STEP

STEW

STRM

STXS

SUMO

SUNW

SWIM

TACT

TARA

TAST

TBNK

TDUP

TELA

TFFP

TIRX

TNXP

TNYA

TOMZ

Stocks That Hit 52-Week Lows On Wednesday

Photo by Chelsea Pridham on <a href="https://unsplash.com/photos/dbZupjFMbMI">Unsplash</a>
The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.
Winc Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wbev#NYSE">WBEV</a>), a company claiming to be one of the fastest-growing at-scale wineries in the United States, has announced the launch of its newest product: Summer Water Bubbly. <a href="https://www.winc.com/wines/2020-summer-water-ros--12660">Summer Water</a> (SW) is a top-100 brand in Wine Enthusiast and is one of the industries first digitally-launched wine brands to find wholesale success and scale.&nbsp;
Summer Water is the best-selling, ultra-premium domestic ros&eacute; in the U.S. market with 66% year-over-year growth in wholesale depletions, 75% omnichannel volume growth and 88% total omnichannel revenue growth according to Winc&rsquo;s data.&nbsp;
After testing and iterating on this sparkling ros&eacute; on its online platform, the company is expanding the Summer Water product line with Summer Water Bubbly, a sparkling French ros&eacute; that will be available in retail stores nationally just in time for the holiday season.<a href="https://www.winc.com/"> Winc</a> hopes it is adding onto this brand&rsquo;s success at the perfect time &mdash; the holiday season is often the peak selling period for sparkling wine and builds on its rapidly scaling wholesale channel.
Summer Water Bubbly has the potential to catapult growth for its Summer Water portfolio as the sparkling ros&eacute; category is growing at 34%, according to the Nielsen Corp. Winc&rsquo;s proprietary data from its base of younger consumers indicate an increasing appetite for sparkling options too: sparkling is a frequently requested style for portfolio variety.
<h2>About Winc Inc.</h2>
Winc claims it is one of the fastest-growing, at-scale wineries in the United States. Fueled by its data-driven brand development strategy and a true omnichannel distribution network, <a href="https://ir.winc.com/">Winc</a> has grown its selling volume by 80% in the last 2 years and sold more than 430,000 cases in 2020 alone.&nbsp;
Winc&rsquo;s recent initial public offering means it is among companies like Willamette Valley Vineyards Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>), LVMH Moet Hennessy Louis Vuitton SE (EPA: MC) and Andrew Peller Ltd. (TSE: ADW), all of which aim to bring luxury-class wines to their target markets.
Since launching in 2015, the company has built Summer Water into a lifestyle brand, developing a cult following online among influencers, celebrities and casual drinkers. Known for its wildly popular <a href="https://www.summerwater.com/">Summer Water Societ&eacute;</a>, the world&rsquo;s 1st ros&eacute; subscription, the brand has also found acclaim through the support of the nation&rsquo;s top accounts. For example, Summer Water is the official wine of the Hollywood Bowl.&nbsp;
The brand was originally launched with a digital strategy, but after seeing success in its first few months in Southern California and Whole Foods Market Inc. stores, now has a national footprint across numerous major retail chains and restaurants.
&ldquo;Winc has a unique opportunity to innovate in our category and SW serves as a case study for our model. Through digital marketing and scaled at-home trial with the younger apex consumer, we have built a leading national ros&eacute; brand. We believe this release is the next step in building on this valuable franchise and executing on our long-term vision for omnichannel growth,&rdquo; said Winc&rsquo;s Co-Founder and President Brian Smith.
The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Emerging Markets

WBEV

Winc Inc. Launches Summer Water Bubbly Rosé Just as the Holiday Season Begins

<h3>Gainers</h3>
<ul>
<li>Protagonist Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptgx#NASDAQ">PTGX</a>) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics&rsquo; rusfertide clinical studies. Northland Capital Markets upgraded the stock from Market Perform to Outperform.</li>
<li>Adamas Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adms#NASDAQ">ADMS</a>) rose 75.1% to settle at $8.07. Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $9.10 per share, or $450 million.</li>
<li>Flexion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flxn#NASDAQ">FLXN</a>) surged 58.7% to close at $9.17. Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash, plus one contingent value right (CVR) worth up to $8.00 per share in cash.</li>
<li>ESS Tech Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gwh#NYSE">GWH</a>) gained 26.9% to settle at $10.42.</li>
<li>U.S. Well Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/usws#NASDAQ">USWS</a>) gained 25.8% to close at $3.02 in sympathy with the price of oil amid increased demand and limited supply.</li>
<li>Trevi Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvi#NASDAQ">TRVI</a>) climbed 24% to close at $1.50 after the company filed Friday to withdraw its offering of shares.</li>
<li>Sphere 3D Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/any#NASDAQ">ANY</a>) surged 23.8% to close at $8.28.</li>
<li>Gaotu Techedu Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NASDAQ">GOTU</a>) surged 19.4% to close at $4.01.</li>
<li>Blue Apron Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) jumped 17.4% to close at $8.03.</li>
<li>Amplify Energy Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ampy#NYSE">AMPY</a>) gained 16% to settle at $3.98.</li>
<li>Synaptogenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpx#NASDAQ">SNPX</a>) surged 15.6% to close at $12.79.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) jumped 15.4% to close at $11.25. Traders circulated Oct. 7 FDA approval for the company&rsquo;s Dextenza.</li>
<li>Xiaobai Maimai Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hx#NASDAQ">HX</a>) gained 15.4% to settle at $3.29.</li>
<li>Statera Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stab#NASDAQ">STAB</a>) surged 15.3% to settle at $2.57.</li>
<li>Dutch Bros Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bros#NYSE">BROS</a>) gained 14.8% to close at $49.00. JPMorgan initiated coverage of Dutch Bros with an Overweight rating and $47 price target, suggesting a 2% downside.</li>
<li>Willamette Valley Vineyards, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>) jumped 14.5% to close at $14.66.</li>
<li>Ra Medical Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmed#NASDAQ">RMED</a>) surged 14.4% to close at $3.34.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgc#NASDAQ">RGC</a>) rose 13.7% to close at $21.72.</li>
<li>SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>) surged 13.5% to close at $18.39 after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $25 price target.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) gained 12.5% to settle at $3.07 after the company received favorable ruling in Inter Partes Review against United Therapeutics patent.</li>
<li>Radius Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdus#NASDAQ">RDUS</a>) rose 11.4% to close at $15.01.</li>
<li>Nutriband Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntrb#NASDAQ">NTRB</a>) shares surged 10.5% to settle at $7.40 after dropping over 14% on Friday.</li>
<li>Matinas BioPharma Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtnb#NASDAQ">MTNB</a>) gained 9.4% to close at $1.16.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) climbed 7.5% to settle at $12.60.</li>
<li>Katapult Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kplt#NASDAQ">KPLT</a>) gained 6.4% to close at $4.84. Katapult Holdings became an Accelerate partner in the Adobe Exchange Program.</li>
<li>EZFill Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezfl#NASDAQ">EZFL</a>) gained 6.3% to close at $3.68 after the company announced it has purchased 33 additional fuel trucks, more than tripling the size of its delivery fleet.</li>
<li>Innoviz Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/invz#NASDAQ">INVZ</a>) rose 5.2% to close at $4.89.</li>
<li>TETRA Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tti#NYSE">TTI</a>) rose 4.7% to close at $3.58 in sympathy with the price of oil amid increased demand and limited supply.</li>
</ul>

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>Cipher Mining Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cifr#NASDAQ">CIFR</a>) shares dipped 22.2% to close at $6.14 on Monday.</li>
<li>LSB Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lxu#NYSE">LXU</a>) fell 20.7% to settle at $9.87.</li>
<li>AeroCentury Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acy#NYSE">ACY</a>) shares dropped 19.1% to close at $49.35.</li>
<li>Immuneering Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrx#NASDAQ">IMRX</a>) dipped 18.4% to settle at $22.60. Immuneering reported compelling preclinical data on IMM-1-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.</li>
<li>Onion Global Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/og#NYSE">OG</a>) dropped 17.7% to close at $8.83.</li>
<li>SecureWorks Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scwx#NASDAQ">SCWX</a>) shares fell 17.4% to close at $19.18.</li>
<li>Tenaya Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnya#NASDAQ">TNYA</a>) dipped 15.7% to close at $20.11.</li>
<li>National CineMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncmi#NASDAQ">NCMI</a>) dropped 14.6% to settle at $3.22.</li>
<li>Power REIT (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pw#NYSE">PW</a>) fell 14.3% to close at $50.59.</li>
<li>Reliance Global Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reli#NASDAQ">RELI</a>) dipped 13.8% to close at $2.30.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) fell 13.5% to settle at $4.80 after jumping around 45% on Friday.</li>
<li>Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) dropped 12.9% to close at $26.46.</li>
<li>eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) fell 12.6% to close at $10.35. eFFECTOR Therapeutics, in collaboration with Baylor College of Medicine, recently announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC).</li>
<li>Hyliion Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hyln#NYSE">HYLN</a>) dropped 11.8% to close at $6.90 after UBS downgraded the stock from Neutral to Sell and lowered its price target from $14 to $5.</li>
<li>PagSeguro Digital Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pags#NASDAQ">PAGS</a>) fell 11.5% to close at $32.37 after dropping 19% on Friday.</li>
<li>BEST Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/best#NYSE">BEST</a>) fell 11.1% to close at $1.84.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) fell 8.3% to close at $9.47.</li>
<li>MeaTech 3D Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mitc#NASDAQ">MITC</a>) fell 5.3% to settle at $8.04. Meatech 3D recently said it is partnering with a collective led by Ashton Kutcher and Guy Oseary, together with strategic players like Effie Epstein, to accelerate growth in developing, commercializing cultured meat production technologies.</li>
</ul>

ADMS

AMPY

APRN

BEST

BROS

CIFR

DATS

EFTR

EZFL

FLXN

GSX Techedu Inc. American Depositary Shares

GOTU

HYLN

ICVX

IMRX

INVZ

KPLT

LQDA

MITC

MTNB

NCMI

NTRB

OCUL

PAGS

PTGX

RDUS

RELI

RMED

SCWX

SNPX

SOFI

STAB

TRVI

USWS

VYGR

46 Biggest Movers From Yesterday

<h3>Gainers</h3>
<ul>
<li>Protagonist Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptgx#NASDAQ">PTGX</a>) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics&rsquo; rusfertide clinical studies. Northland Capital Markets upgraded the stock from Market Perform to Outperform.</li>
<li>Adamas Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adms#NASDAQ">ADMS</a>) gained 74% to $8.04. Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $9.10 per share, or $450 million.</li>
<li>Flexion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flxn#NASDAQ">FLXN</a>) gained 60.9% to $9.30. Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash, plus one contingent value right (CVR) worth up to $8.00 per share in cash.</li>
<li>U.S. Well Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/usws#NASDAQ">USWS</a>) jumped 29.6% to $3.1099 in sympathy with the price of oil amid increased demand and limited supply.</li>
<li>EZFill Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezfl#NASDAQ">EZFL</a>) surged 17% to $4.0790 after the company announced it has purchased 33 additional fuel trucks, more than tripling the size of its delivery fleet.</li>
<li>Blue Apron Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) gained 16.2% to $7.95.</li>
<li>Gaotu Techedu Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NASDAQ">GOTU</a>) rose 16% to $3.9250.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) surged 15% to $11.21. Traders circulated Oct. 7 FDA approval for the company&rsquo;s Dextenza.</li>
<li>Katapult Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kplt#NASDAQ">KPLT</a>) rose 13.2% to $5.18. Katapult Holdings became an Accelerate partner in the Adobe Exchange Program.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) gained 13% to $13.24.</li>
<li>TETRA Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tti#NYSE">TTI</a>) rose 12.8% to $3.86 in sympathy with the price of oil amid increased demand and limited supply.</li>
<li>Innoviz Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/invz#NASDAQ">INVZ</a>) gained 12.3% to $5.22.</li>
<li>Willamette Valley Vineyards, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>) surged 11.3% to $14.25.</li>
<li>Nutriband Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntrb#NASDAQ">NTRB</a>) shares gained 10.5% to $7.40 after dropping over 14% on Friday.</li>
<li>Trevi Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvi#NASDAQ">TRVI</a>) gained 10% to $1.33 after the company filed Friday to withdraw its offering of shares.</li>
<li>Matinas BioPharma Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtnb#NASDAQ">MTNB</a>) rose 8.5% to $1.1501.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) rose 7.9% to $7.40 after the company received favorable ruling in Inter Partes Review against United Therapeutics patent.</li>
<li>AIkido Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aiki#NASDAQ">AIKI</a>) shares rose 6.8% to $0.9289. HC Wainwright &amp; Co. initiated coverage on AIkido Pharma with a Buy rating and announced a price target of $2.</li>
</ul>

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>Cipher Mining Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cifr#NASDAQ">CIFR</a>) shares dropped 18.8% to $6.41.</li>
<li>AeroCentury Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acy#NYSE">ACY</a>) shares fell 14% to $52.44.</li>
<li>SecureWorks Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scwx#NASDAQ">SCWX</a>) shares declined 13.3% to $20.13.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) dropped 11.3% to $4.92 after jumping around 45% on Friday.</li>
<li>PagSeguro Digital Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pags#NASDAQ">PAGS</a>) fell 11.1% to $32.51 after dropping 19% on Friday.</li>
<li>MeaTech 3D Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mitc#NASDAQ">MITC</a>) dropped 10.3% to $7.62. Meatech 3D recently said it is partnering with a collective led by Ashton Kutcher and Guy Oseary, together with strategic players like Effie Epstein, to accelerate growth in developing, commercializing cultured meat production technologies.</li>
<li>eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) fell 9.7% to $10.69. eFFECTOR Therapeutics, in collaboration with Baylor College of Medicine, recently announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC).</li>
<li>Hyliion Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hyln#NYSE">HYLN</a>) dropped 9% to $7.11 after UBS downgraded the stock from Neutral to Sell and lowered its price target from $14 to $5.</li>
<li>BEST Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/best#NYSE">BEST</a>) fell 8.2% to $1.8997.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) dropped 7.5% to $9.56.</li>
</ul>

AIKI

28 Stocks Moving In Monday's Mid-Day Session

Benzinga&rsquo;s weekly Stock Wars matches up two leaders in a major industry sector, with the goal of determining which company is the better investment.
This week, the duel is between two wine industry companies:&nbsp;The Duckhorn Portfolio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/napa#NYSE">NAPA</a>) and Willamette Valley Vineyards, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>).
The Case For The Duckhorn Portfolio:&nbsp;Founded in 1976&nbsp;by Dan and Margaret Duckhorn when they&nbsp;opened&nbsp;their merlot-focused Duckhorn Vineyards in California&rsquo;s Napa Valley, this company encompasses 10 wineries, eight winemaking facilities, seven tasting rooms and more than 800 acres of vineyards spanning 22 estate properties.
The company&rsquo;s luxury wine brands include Duckhorn Vineyards, Decoy, Kosta Browne, Goldeneye, Paraduxx, Calera, Migration, Canvasback, Greenwing and Postmark, with wines retailing from $20 to $200 and are sold across the U.S. and in 50 countries.
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/UXb9Xceg_C0" width="560"></iframe>
The private equity firm TSG Consumer Partners LLC acquired Duckhorn from another private equity firm, GI Partners, in 2016. The company held its initial public offering on March 17, 2021, with 20 million shares of its common stock to the public&nbsp;with 13.3 million shares being offered by Duckhorn and the remainder offered by its existing stockholder at $15&nbsp;per share.
According to a <a href="https://www.bloomberg.com/news/articles/2021-03-18/napa-valley-winemaker-duckhorn-rises-after-300-million-ipo">Bloomberg</a> report, the shares rose as much as 29% during the first day of trading and closed at $17.18, giving the company a market value of $1.98 billion.
In its most recent earnings report, the fiscal year fourth-quarter&nbsp;data published on Oct. 4, the company reported net sales of $70.9 million, up from $52.2 million in the prior year, and a gross profit of $34.4 million, up from $25.9 million one year before.
Duckhorn&rsquo;s net income was $7.4 million, or 6 cents per diluted share, versus a net loss of $2.7 million, or -3 cents per diluted share, in the prior-year period, while its adjusted net income was $9.2 million, or 8 cents per diluted share, versus $7.4 million, or 7 cents per diluted share, one year earlier.
&ldquo;Our brand equity, diversified omnichannel platform and highly flexible supply chain position us very well to capitalize on the heightened interest and demand for high-quality wine, all of which contributed to another period of robust sales and volume growth,&rdquo; said chairman and CEO Alex Ryan. &ldquo;Importantly, we continue to achieve profitable results in an environmentally sustainable manner.&rdquo;
Duckhorn opened for trading on Wednesday at $21.49; since going public roughly seven months ago, its shares have traded in the range of $16.16 to $25.25.
Related Link:&nbsp;<a href="https://www.benzinga.com/topic/stock-wars">The complete Stock Wars series</a>
The Case For Willamette Valley Vineyards: Named after the&nbsp;Oregon region, this company was founded in 1983 by Jim Bernau and Don Voorhies and has become acclaimed over the years for its pinot noir, pinot gris and chardonnay.
In September 1988, the company made history when Bernau received approval from the U.S. Securities and Exchange Commission to conduct the first successful self-underwritten Regulation A public offering. By the time this initiative concluded in May 1989, Bernau achieved the nation&rsquo;s first &ldquo;crowdfunded&rdquo; consumer-owned business with approximately 1,000 investing an average of $1,500 each.
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/f6w5aURqeEQ" width="560"></iframe>
In its most recent earnings report, the second-quarter&nbsp;data published on Aug. 12, the company reported sales revenue of $8.9 million, up from $5.5 million one year earlier, and a gross profit of $5.1 million, up from $3.5 million in the previous year.
The second-quarter&nbsp;net income was just over $1 million with earnings per common share at 14 cents, compared to $620,421 in net income and 7 cents worth of earnings per common share in the previous year.
&ldquo;Our wine sales directly to wine enthusiasts and to our wholesalers&#39; accounts has never been higher during this first six months of 2021,&rdquo; said Bernau. &ldquo;While labor shortages and supply chain disruptions have been challenging, we remain on course to open our new sparkling winery near Dundee and winery restaurants as planned. The construction of an additional 50,000 cases of fermentation capacity is on schedule and expected to be ready before what now appears to be one of Oregon&#39;s earliest harvests.&rdquo;
Willamette Valley Vineyards opened for trading on Wednesday at $12.95, sandwiched between its 52-week range of $6 and $16.54.
The Verdict: Relatively few wine industry companies are publicly traded, which is not surprising when one considers the distinctive challenges involved in wine production, ranging from the impact of weather on grape crops to the aging process required before the finished products can be sold. This is not an item that can be manufactured in a rapid assembly-line process.
The U.S. wine industry recorded 27 consecutive annual gains through 2020 but is expected to see a 0.5% volume decrease this year, down to 335.4 million 9-liter cases, according to the 2021 edition of &ldquo;The U.S. Wine Market: Shanken&rsquo;s Impact Databank Review &amp; Forecast.&rdquo;
&ldquo;While the U.S. has been the world&rsquo;s largest wine-consuming market since 2013, volume growth has been modest at best in each of the past 10 years due to fierce competition from whiskies, hard seltzer, and other ready-to-drink brands,&rdquo; the Shanken report said. &ldquo;While the wine industry registered an above-average 2% volume increase last year owing to off-premise gains during the pandemic, wine continues to lose market share to spirits and flavored malt beverages.&rdquo;
If The Duckhorn Portfolio and Willamette Valley Vineyards seem to be on the smallish side in terms of revenue, consider that the only U.S. brand with more than $1 billion in retail sales is Barefoot Cellars from Grape Links Inc.
In choosing which of these two stocks is the strongest, Willamette Valley Vineyards clearly has a track record of success and its Oregon wines are holding their own in a highly competitive market &mdash;&nbsp;only 1% of U.S. wine is sourced from Oregon.
But, The Duckhorn Portfolio came roaring out of the IPO tunnel like a freight train and is trading higher than its well-established rival. Even with seven months in trading,
The Duckhorn Portfolio is still at a ground-floor level for investors looking for long-term growth. For that reason, we raise our Stock Wars glass in cheers to The Duckhorn Portfolio as the better investment in this duel of shares.
Photo: Arek Socha from Pixabay.

Education

Opinion

Stock Wars: The Duckhorn Portfolio Vs. Willamette Valley Vineyards

Rumors

Politics

BF/A

BF/B

Hearing Democratic Senators Have Asked US Pres Biden To End Wine Tariffs; Spirits/Wine Stocks Quiet

<h3>Gainers</h3>
<ul>
<li>ShiftPixy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pixy#NASDAQ">PIXY</a>) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs.</li>
<li>Takung Art Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tkat#NASDAQ">TKAT</a>) surged 24.2% to close at $39.11</li>
<li>JAKKS Pacific, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jakk#NASDAQ">JAKK</a>) gained 23.4% to close at $9.05 after the company reported better-than-expected Q1 results.</li>
<li>Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) climbed 22.8% to settle at $8.12 after the company announced updated results from its Phase 1/2 pilot trial of GC4419, versus placebo, in patients with locally advanced pancreatic cancer who are undergoing stereotactic body radiation therapy.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) gained 22.7% to close at $19.16. Ocular Therapeutix, reported multiple scientific presentations at the Association for Research in Vision and Ophthalmology Annual Meeting.</li>
<li>1-800-FLOWERS.COM, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flws#NASDAQ">FLWS</a>) jumped 20.5% to close at $29.89 after the company reported better-than-expected Q3 results.</li>
<li>Willamette Valley Vineyards, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wvvi#NASDAQ">WVVI</a>) gained 19.6% to close at $12.25 on Thursday.</li>
<li>SkyWater Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skyt#NASDAQ">SKYT</a>) rose 16.9% to close at $21.77. The company, last week, priced its IPO at $14 per share.</li>
<li>VEREIT, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ver#NYSE">VER</a>) jumped 16% to close at $47.88 after the company announced an all-stock merger agreement with Realty Income.</li>
<li>MEDIROM Healthcare Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrm#NASDAQ">MRM</a>) gained 15.2% to close at $10.31.</li>
<li>Sharps Compliance Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smed#NASDAQ">SMED</a>) surged 15% to close at $18.41 on continued upward momentum after the company reported better-than-expected Q3 EPS and sales results. Following earnings, HC Wainwright &amp; Co maintained a Buy and raised its price target from $18 to $25.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capr#NASDAQ">CAPR</a>) shares jumped 14.9% to close at $4.54 after the company signed exclusive worldwide license agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics as part of the company&#39;s exosome technology portfolio.</li>
<li>Communications Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jcs#NASDAQ">JCS</a>) gained 14.5% to close at $6.73 as the company agreed to sell its Transition Networks and Net2Edge businesses to Lantronix.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enlv#NASDAQ">ENLV</a>) surged 14.2% to settle at $12.10.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dlpn#NASDAQ">DLPN</a>) shares rose 13.2% to close at $12.99. Dolphin Entertainment recently reported better-than-expected Q4 sales results.</li>
<li>Century Communities, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccs#NYSE">CCS</a>) gained 13.1% to settle at $74.94 after the company reported better-than-expected Q1 EPS and sales results. The company also raised its FY21 sales guidance.</li>
<li>GreenBox POS (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbox#NASDAQ">GBOX</a>) surged 13.1% to close at $11.35.</li>
<li>North American Construction Group Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noa#NYSE">NOA</a>) gained 12.5% to close at $13.28 after the company reported Q1 earnings results.</li>
<li>Extreme Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/extr#NASDAQ">EXTR</a>) climbed 12.4% to close at $12.01. The company recently reported better-than-expected Q3 results.</li>
<li>Summer Infant, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sumr#NASDAQ">SUMR</a>) gained 12% to settle at $18.91.</li>
<li>Nokia Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nok#NYSE">NOK</a>) shares jumped 11.2% to close at $4.67 after reporting upbeat Q1 results.</li>
<li>Realogy Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rlgy#NYSE">RLGY</a>) climbed 10.4% to close at $16.83 following upbeat quarterly results.</li>
<li>Alliance Data Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ads#NYSE">ADS</a>) jumped 10% to close at $118.64 following upbeat Q1 results.</li>
<li>Vaxart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vxrt#NASDAQ">VXRT</a>) climbed 9.1% to settle at $9.21 as the company said its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the World Vaccine Congress Washington that will be held virtually from May 4-6, 2021.</li>
<li>Bloomin&#39; Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blmn#NASDAQ">BLMN</a>) rose 8.9% to settle at $31.38 after the company reported better-than-expected Q1 results.</li>
<li>MRC Global Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrc#NYSE">MRC</a>) surged 8.9% to close at $9.87. The company recently released Q1 results.</li>
<li>AtriCure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atrc#NASDAQ">ATRC</a>) gained 8.8% to close at $76.00 after the company reported that its EPi-Sense System was approved by the FDA for treatment of long-standing persistent afib patients.</li>
<li>Facebook, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fb#NASDAQ">FB</a>) rose 7.3% to close at $329.51 after the company reported upbeat results for its first quarter on Wednesday. The company reported 1.88 billion daily active users, up 8% year-over-year, as well as 2.85 billion monthly active users, up 10% year-over-year.</li>
<li>Cheesecake Factory Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cake#NASDAQ">CAKE</a>) rose 7.1% to settle at $63.20 after reporting higher quarterly earnings.</li>
<li>QUALCOMM Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qcom#NASDAQ">QCOM</a>) rose 4.5% to close at $142.68 after the company reported better-than-expected Q2 results and issued strong Q3 EPS guidance.</li>
</ul>
&nbsp;
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>Adverum Biotechnologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/advm#NASDAQ">ADVM</a>) shares tumbled 62.3% to close at $3.83 on Thursday after the company announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.</li>
<li>Farmmi, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fami#NASDAQ">FAMI</a>) fell 54.7% to close at $0.3580 after the company priced its $42.0 million upsized underwritten public offering of ordinary shares.</li>
<li>Cara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cara#NASDAQ">CARA</a>) dropped 45.4% to close at $14.07 after the company announced mixed topline results from its KARE Phase 2 dose-ranging clinical trial of oral Korsuva for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients. The company said the study did not meet the primary endpoint of worst-itch NRS change from baseline at week 12 or secondary endpoint of 4-point responder analysis in the intent-to-treat patient population. However, the study achieved primary endpoint of worst-itch NRS change and secondary endpoint of 4-point responder analysis in pre-specified analyses of mild-to-moderate AD patients, comprising 64% of ITT population.</li>
<li>Atomera Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atom#NASDAQ">ATOM</a>) fell 24.8% to close at $16.68 after the company reported Q1 earnings results.</li>
<li>Palisade Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pali#NASDAQ">PALI</a>) fell 23.9% to close at $7.80.</li>
<li>Brooklyn ImmunoTherapeutics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/btx#NYSE">BTX</a>) dipped 21.8% to close at $34.22. Brooklyn ImmunoTherapeutics acquired license for mRNA technology platform of Factor Bioscience Limited And Novellus Therapeutics Limited.</li>
<li>Brightcove Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcov#NASDAQ">BCOV</a>) dipped 20% to settle at $15.56 after the company issued Q2 EPS and sales guidance below estimates.</li>
<li>Tiptree Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tipt#NASDAQ">TIPT</a>) fell 19.5% to close at $10.10 after the company reported it has decided to withdraw the registration statement relating to previously announced IPO by Fortegra due to &lsquo;prevailing market conditions and the high value.&rsquo;</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) dropped 19.4% to settle at $46.81 after reporting a decline in quarterly earnings.</li>
<li>Vyant Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vynt#NASDAQ">VYNT</a>) fell 19.1% to close at $3.76 after climbing 16% on Wednesday. Vyant Bio, Ordaōs Bio and Cellaria, recently announced collaboration to &#39;design and qualify biomarker-specific small protein therapeutics.&#39;</li>
<li>Selecta Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/selb#NASDAQ">SELB</a>) dipped 19% to close at $3.15. Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences.</li>
<li>FormFactor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/form#NASDAQ">FORM</a>) fell 18.2% to close at $39.22 after the company reported worse-than-expected Q1 EPS results.</li>
<li>Regional Health Properties, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rhe#NYSE">RHE</a>) dropped 17.9% to close at $5.23.</li>
<li>Galectin Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/galt#NASDAQ">GALT</a>) shares fell 16.9% to settle at $4.24 after jumping over 22% on Wednesday. The company recently announced neurosurgeon Dr. Ben Carson, Sr. joined the team as a special consultant to accelerate and enhance development of the company&#39;s galectin-3 inhibitor, belapectin.</li>
<li>Cohu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cohu#NASDAQ">COHU</a>) dipped 16.9% to close at $38.85 after reporting Q1 results.</li>
<li>22nd Century Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NYSE">XXII</a>) fell 15.7% to settle at $4.74.</li>
<li>Resolute Forest Products Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rfp#NYSE">RFP</a>) fell 15.4% to close at $13.17 after reporting preliminary Q1 results.</li>
<li>Coeur Mining, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) dropped 14.4% to settle at $8.23 after the company reported worse-than-expected Q1 EPS and sales results.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) fell 14.3% to close at $3.61.</li>
<li>MicroVision, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvis#NASDAQ">MVIS</a>) dipped 14.2% to close at $18.00.</li>
<li>Aspen Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azpn#NASDAQ">AZPN</a>) fell 13.2% to settle at $132.64 after the company reported worse-than-expected Q3 EPS and sales results. The company also issued FY21 EPS and sales guidance below analyst estimates.</li>
<li>Cree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cree#NASDAQ">CREE</a>) fell 12.6% to close at $98.53 after the company issued Q4 EPS guidance below analyst estimates. JP Morgan also downgraded the stock from Neutral to Underweight.</li>
<li>Nemaura Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmrd#NASDAQ">NMRD</a>) fell 12.6% to close at $4.73.</li>
<li>Smart Share Global Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/em#NASDAQ">EM</a>) dropped 12.5% to settle at $8.06.</li>
<li>Ribbon Communications Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rbbn#NASDAQ">RBBN</a>) dipped 11.9% to close at $7.17 following weak quarterly sales.</li>
<li>eBay Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) fell 10% to settle at $56.07. eBay reported upbeat Q1 earnings, but issued weak earnings guidance for the current quarter.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) fell 9.9% to close at $57.10 on reports the US Labor Secretary said most US gig workers should be classified as employees.</li>
<li>Ford Motor Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/f#NYSE">F</a>) fell 9.4% to close at $11.26 after the company reported Q1 earnings results.</li>
<li>ServiceNow, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/now#NYSE">NOW</a>) fell 9.4% to settle at $505.00 after the company reported Q1 earnings results.</li>
<li>Peabody Energy Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/btu#NYSE">BTU</a>) dropped 9.3% to close at $3.89 following quarterly results.</li>
<li>Hologic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) fell 8.5% to settle at $66.23 after the company reported worse-than-expected Q2 results and issued weak Q3 guidance.</li>
<li>Teladoc Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NASDAQ">TDOC</a>) fell 8.3% to close at $170.86 after reporting Q1 results.</li>
<li>American Shared Hospital Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ams#NYSE">AMS</a>) dropped 8.3% to close at $2.44.</li>
<li>Citrix Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctxs#NASDAQ">CTXS</a>) dropped 7.6% to close at $128.02 after the company reported worse-than-expected Q1 results.</li>
<li>Tenaris S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ts#NYSE">TS</a>) fell 7.2% to close at $21.02 after the company reported Q1 results.</li>
</ul>

Comments

Willamette Valley

Willamette Valley (WVVI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga